[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355819-105":59,"doc-detail-355819-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cost-effectiveness-analysis-of-a-bone-metastasis-cancer-board-for-skeletal-related-events-of-breast-cancer","Cost-effectiveness analysis of a bone metastasis cancer board for skeletal-related events of breast cancer","","Objective: evaluate the cost-effectiveness of breast cancer treatment strategies with bone metastasis, comparing approaches developed with versus without a multidisciplinary bone metastasis cancer board. Methods: a single-center retrospective cohort (July 2021–May 2025) used published data and consecutive patient data to build a decision-tree model plus a Markov model from a healthcare payer perspective. Effectiveness was measured in quality-adjusted life years, with deterministic and probabilistic sensitivity analyses. Results and conclusions support board-enabled strategies for resource allocation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cost-effectiveness-analysis-of-a-bone-metastasis-cancer-board-for-skeletal-related-events-of-breast-cancer/355819/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cost-effectiveness-analysis-of-a-bone-metastasis-cancer-board-for-skeletal-related-events-of-breast-cancer/355819.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective regarding the bone metastasis cancer board?","Question",{"text":112,"@type":113},"To evaluate the cost-effectiveness of treatment strategies for patients with breast cancer and bone metastasis, comparing strategies developed with and without multidisciplinary bone metastasis cancer board involvement.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were costs and effectiveness assessed in the study?",{"text":117,"@type":113},"A decision-tree model for diagnosis and treatment and a Markov model for long-term follow-up were used from a healthcare payer’s perspective. Effectiveness was measured in quality-adjusted life years, with one-month cycles and health states including alive without SRE, alive with SRE, and death.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about incremental cost-effectiveness?",{"text":121,"@type":113},"The strategy developed using bone metastasis cancer board inputs was more cost-effective, with an incremental cost-effectiveness ratio below the Japanese willingness-to-pay threshold of 5 million Japanese yen per quality-adjusted life year.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355819,1790595542,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cost-effectiveness analysis of a bone metastasis cancer board for skeletal-related events of breast cancer  \nSatoru Yanagaki1 , * , Shinichirou Yoshida2 , Sota Oguro3 , Shin Hitachi4 , Hiroshi Tada5 , Yojiro Ishikawa1 , Munenori Watanuki6 , Jun Iwatsu2 , Hirotaka Kurata2 , Toshimi Aizawa2 , Takayuki Yamada1 , Kei Takase3  \n1 Department of Radiology, Tohoku Medical Pharmaceutical University Hospital, Sendai, Miyagi, 983-8536, Japan  \n2 Department of Orthopaedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan  \n3 Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, 980-8574, Japan  \n4 Department of Diagnostic Radiology, Takeda General Hospital, Aizuwakamatsu, Fukushima, 965-8585, Japan  \n5 Division of Breast and Endocrine Surgery, Tohoku Medical Pharmaceutical University Hospital, Sendai, Miyagi, 983-8536, Japan  \n6 Department of Orthopaedic Surgery, JR Sendai Hospital, Sendai, Miyagi, 980-0022, Japan  \n*Corresponding author. Department of Radiology, Tohoku Medical Pharmaceutical University Hospital, Chome-15-1 Fukumuro, Miyagino Ward, Sendai,  \nMiyagi, Japan. E-mail: [satoru.yanagaki.c7@tohoku.ac.jp](satoru.yanagaki.c7@tohoku.ac.jp)  \nAbstract  \nObjective: To evaluate the cost-effectiveness of treatment strategies for patients with breast cancer and bone metastasis (BM) developed with and without the involvement of a multidisciplinary BM cancer board.  \nMethods: In this single-center retrospective cohort study, we used previously published data and the data obtained from consecutive patients diagnosed with breast cancer and BM referred to the Tohoku University Hospital between July 2021 and May 2025. We developed a model combining a decision tree for the diagnosis and treatment phases of breast cancer and BMand a Markov model for long-term follow-up to evaluate the cost-effectiveness from a healthcare payer’s perspective. The model included three health states: alive without skeletal-related event (SRE), alive with SRE, and death, with 1-month cycles. Effectiveness was measured in quality-adjusted life years. Deterministic and probabilistic sensitivity analyses were also performed.  \nResults: The strategy developed using BM cancer board inputs demonstrated superior cost-effectiveness; the incremental cost-effectiveness ratio was below the Japanese willingness-to-pay threshold of 5 million Japanese yen per quality-adjusted life year. Sensitivity analysis confirmed robustness of these results, with a tornado diagram identifying the key influential parameter: the probability of treatable BM inthe BM cancer board strategy. In the probabilistic sensitivity analysis with 10 000 Monte Carlo simulations, more than half of the estimates fell below the willingness-to-pay threshold.  \nConclusions: The treatment strategy developed by involving a BM cancer board is more cost-effective than that developed without involving such a board, justifying healthcare resource allocation for implementation of this board.  \nKeywords bone metastasis, cost-effectiveness analysis, cancer board, skeletal-related event  \nIntroduction  \nBone metastasis (BM) is a common distant disease spread in many solid cancers, particularly in malignancies of the lung, breast, and prostate, occurring during the disease course [1–4] . In addition to conventional radiation therapy and surgery, numerous treatment options for BM have emerged in recent years, including medical treatment with bone-modifying agents, such as zoledronic acid and denosumab, and interventional radiology techniques, such as percutaneous vertebroplasty and radiofrequency ablation [1, 5, 6] .  \nWhen determining diagnosis and treatment strategies, multidisciplinary collaboration involving specialties such as orthopedics, radiology, and pathology is crucial [7] . Recent research has highlighted the importance of cross-disciplinary specialized bone metastasis cancer boards (BMCBs) for improved diagnostic accuracy and pat","cbCaihTrwzpRqzVw","https://ap.wps.com/l/cbCaihTrwzpRqzVw","pdf",943448,"English","# Abstract\n## Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Background on bone metastasis\n## Multidisciplinary bone metastasis cancer boards\n## Role of cost-effectiveness analysis in healthcare","[{\"question\":\"What was the study objective regarding the bone metastasis cancer board?\",\"answer\":\"To evaluate the cost-effectiveness of treatment strategies for patients with breast cancer and bone metastasis, comparing strategies developed with and without multidisciplinary bone metastasis cancer board involvement.\"},{\"question\":\"How were costs and effectiveness assessed in the study?\",\"answer\":\"A decision-tree model for diagnosis and treatment and a Markov model for long-term follow-up were used from a healthcare payer’s perspective. Effectiveness was measured in quality-adjusted life years, with one-month cycles and health states including alive without SRE, alive with SRE, and death.\"},{\"question\":\"What did the results show about incremental cost-effectiveness?\",\"answer\":\"The strategy developed using bone metastasis cancer board inputs was more cost-effective, with an incremental cost-effectiveness ratio below the Japanese willingness-to-pay threshold of 5 million Japanese yen per quality-adjusted life year.\"}]","Cost-effectiveness analysis of a bone metastasis cancer board for skeletal-related events of breast cancer | PDF",1790121186,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0001883fb6b4e376aa5263a1cdb24b06.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cbdd2e76efd63303eab285620300a70.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c10ffe92d750f4ddad1557e0f896213.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abeb592ce410437044f809dada71c9bc.webp",980,1287]